Chardan Capital lowered shares of Assembly Biosciences (NASDAQ:ASMB) from a buy rating to a neutral rating in a research note published on Friday morning, MarketBeat.com reports. They currently have $50.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $35.00.
A number of other analysts also recently issued reports on ASMB. B. Riley started coverage on shares of Assembly Biosciences in a report on Friday, January 5th. They issued a neutral rating and a $35.00 price objective for the company. BidaskClub downgraded shares of Assembly Biosciences from a buy rating to a hold rating in a report on Saturday, January 6th. Zacks Investment Research downgraded shares of Assembly Biosciences from a buy rating to a hold rating in a report on Monday, January 15th. ValuEngine raised shares of Assembly Biosciences from a sell rating to a hold rating in a report on Saturday, February 3rd. Finally, Jefferies Group boosted their price objective on shares of Assembly Biosciences to $75.00 and gave the company a buy rating in a report on Thursday, March 8th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Assembly Biosciences currently has a consensus rating of Hold and a consensus price target of $58.00.
NASDAQ ASMB opened at $44.93 on Friday. The stock has a market capitalization of $915.85, a price-to-earnings ratio of -18.64 and a beta of 0.74. Assembly Biosciences has a 12-month low of $18.60 and a 12-month high of $67.36.
In other news, Director William R. Ringo sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $56.37, for a total transaction of $56,370.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 3,000 shares of company stock valued at $152,550. 19.60% of the stock is currently owned by insiders.
Institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. lifted its holdings in shares of Assembly Biosciences by 6.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 177,312 shares of the biopharmaceutical company’s stock worth $5,944,000 after acquiring an additional 11,412 shares during the period. Virtus Fund Advisers LLC bought a new stake in shares of Assembly Biosciences during the 4th quarter worth approximately $361,000. Arthur M. Cohen & Associates LLC bought a new stake in shares of Assembly Biosciences during the 4th quarter worth approximately $882,000. Perceptive Advisors LLC lifted its holdings in shares of Assembly Biosciences by 21.5% during the 4th quarter. Perceptive Advisors LLC now owns 536,626 shares of the biopharmaceutical company’s stock worth $24,282,000 after acquiring an additional 94,793 shares during the period. Finally, Emerald Advisers Inc. PA bought a new stake in shares of Assembly Biosciences during the 4th quarter worth approximately $8,673,000. 76.17% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/17/assembly-biosciences-asmb-downgraded-to-neutral-at-chardan-capital.html.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.